Press Releases
Date picker
Category
Results per page
Kancera provides operational update
Kancera hereby provides an operational update on the PFKFB3 and HDAC6 projects as well as the EU-funded epigenetically targeted parasitic project A-PARADDISE.
Interim Report for Kancera AB (publ) Q3 2015. January 1 – September 30, 2015.
Regulatory
The period January to September 2015 and the third quarter 2015 in brief R&D expenses for the period amounted to SEK 12.1m (SEK 9.6m) of which the third quarter constituted…
Kancera provides operational update on the ROR and Fractalkine projects
In connection with a meeting arranged by the Swedish Shareholders' Association in Malmö on September 30, Kancera provides an operational update on the ROR and Fractalkine projects.
Kancera evaluates immuno-oncology drug candidate
Kancera has entered into an agreement with Acturum Life Science AB in order to evaluate and further develop the unique Fractalkine inhibitor AZD8797. Published research points to that Fractalkine signaling…
Interim Report for Kancera AB (publ) Q2 2015, January 1 – June 30, 2015
Regulatory
The period January to June 2014 and the second quarter 2015 in brief R&D expenses for the period amounted to SEK 8.8m (SEK 6.9m) of which the second quarter constituted…
Interim Report for Kancera AB (publ) Q1 2015 January 1 – March 31, 2015
Regulatory
In 2013 Kancera changed from the RFR2 regulations, applicable to companies in groups, to BFN ́s complementary regulation K3. The full year report and consolidated accounts fulfill the requirements of…
Kancera provides operational update on the cancer projects
Kancera reports results from the company's cancer project portfolio generated in 2015.
Full Year Report for Kancera AB (publ) Q4 2014 January 1 – December 31, 2014
Regulatory
In 2013 Kancera changed from the RFR2 regulations, applicable to companies in groups, to BFN ́s complementary regulation K3. The full year report and consolidated accounts fulfill the requirements of…
Kancera provides operational update on the ROR project
Kancera reports that a second efficacy study of the drug candidate KAN0439834 (small molecule inhibitor of ROR1) has been completed in an animal model of an advanced stage of chronic…
Kancera provides operational update on the HDAC6 project
Kancera reports that an investigation of the mechanism of action of the company's patent-pending HDAC6 inhibitors has demonstrated a unique profile that could strengthen the competitiveness of the project.